Immunosuppressants: What's new?

Current Opinion in Organ Transplantation

Volumn 15, Issue 5, 2010, Pages 594-600

  Dell Olio, Dominic ^a   Kelly, Deirdre A ^a  

^a BIRMINGHAM CHILDREN S HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

children; immunosuppression; liver transplantation; new drugs; protocols

Indexed keywords

4 AD11; ALEFACEPT; ALEMTUZUMAB; ATACICEPT; BASILIXIMAB; BELATACEPT; BELIMUMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN A; DACLIZUMAB; ECULIZUMAB; EFALIZUMAB; EPRATUZUMAB; EVEROLIMUS; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; MICRORNA; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; OCRELIZUMAB; OFATUMUMAB; OKT 3; RAPAMYCIN; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ADOLESCENCE; ADULTHOOD; ALLOIMMUNITY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CARDIOMYOPATHY; CELL POPULATION; CHILD; CHRONIC LYMPHATIC LEUKEMIA; CROHN DISEASE; DRUG BLOOD LEVEL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GRAFT REJECTION; GRAFT SURVIVAL; HEMOGLOBINURIA; HUMAN; HYPERLIPIDEMIA; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; LEUKOPENIA; LIVER FUNCTION TEST; LIVER TRANSPLANTATION; MULTIPLE SCLEROSIS; NEPHROTOXICITY; NONHODGKIN LYMPHOMA; PEDIATRIC SURGERY; PSORIASIS; QUALITY OF LIFE; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SEIZURE; SIDE EFFECT; SURVIVOR; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA;

ADOLESCENT; CONTINUITY OF PATIENT CARE; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MEDICATION ADHERENCE; SURVIVORS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77957560314     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e32833d8936     Document Type: Review

References (54)

1. Kelly D, Jara P, Rodeck B., et al. Tacrolimus and steroids versus ciclosporin microemulsion, steroids, and azathioprine in children undergoing liver transplantation: randomised European multicentre trial. Lancet 2004; 364: 1054-1061.
2. Fischer L, Sterneck M, Gahlemann C.G., et al. A prospective study comparing safety and efficacy of mycophenolate mofetil versus azathioprine in primary liver transplant recipients. Transplant Proc 2000; 32: 2125-2127.
3. Arias M, Campistol JM, Vincenti F. Evolving trends in induction therapy. Transplant Rev (Orlando) 2009; 23: 94-102.
4. Watson CJ, Bradley JA Sirolimus and everolimus: inhibitors of mammalian target of rapamycin in liver transplantation. Transpl Rev 2006; 20: 104-114.
5. Dell-Olio D., Kelly DA Calcineurin inhibitor minimization in pediatric liver allograft recipients. Pediatr Transplant 2009; 13: 670-681.
6. Berquist RK, Berquist WE, Esquivel C.O., et al. Nonadherence to posttransplant care: prevalence, risk factors and outcomes in adolescent liver transplant recipients. Pediatr Transplant 2008; 12: 194-200.
7. Soltys KA, Mazariegos GV, Squires R.H., et al. Late graft loss or death in pediatric liver transplantation: an analysis of the SPLIT database. Am J Transplant 2007; 7: 2165-2171.
8. Heneghan MA, Selzner M, Yoshida E.M., Mullhaupt B. Pregnancy and sexual function in liver transplantation. J Hepatol 2008; 49: 507-519.
9. Herrero JI. De novo malignancies following liver transplantation: impact and recommendations. Liver Transpl 2009; 15: S90-S94.
10. Dommergues JP, Letierce A, Gravereau L, et al. Current lifestyle of young adults after liver transplantation during childhood. Am J Transplant 2010; 10: 1-9.
11. Krischock L, Marks SD Induction therapy: why, when, and which agent? Pediatr Transplant 2010; 14: 298-313.
12. Hawksworth JS, Leeser D, Jindal R.M., et al. New directions for induction immunosuppression strategy in solid organ transplantation. Am J Surg 2009; 197: 515-524.
13. Group S.R. Immunosuppression: first transplant. Studies of Pediatric Liver Transplantation 2006. Annual Report, 2006: 5-11.
14. Heimbach JK, Charlton MR Antibody-based immunosuppression following liver transplantation: the plot thickens. Am J Transplant 2010; 10: 445-446.
15. Gaber AO, Monaco AP, Russell J.A., et al. Rabbit antithymocyte globulin (Thymoglobulin): 25 years and new frontiers in solid organ transplantation and haematology. Drugs 2010; 70: 691-732.
16. Bucuvalas JC, Anand R. Treatment with immunoglobulin improves outcome for pediatric liver transplant recipients. Liver Transpl 2009; 15: 1564-1569.
17. Ramirez CB, Doria C, di FF, et al. Anti-IL2 induction in livertransplantation with 93% rejection-free patient and graft survival at 18 months. J Surg Res 2007; 138: 198-204.
18. Al-Sinani S., Dhawan A. Corticosteroids usage in pediatric liver transplantation: to be or not to be! Pediatr Transplant 2009; 13: 160-170.
19. Lerut J, Bonaccorsi-Riani E, Finet P., Gianello P. Minimization of steroids in liver transplantation. Transpl Int 2009; 22: 2-19.
20. Reding R, Pire A, Janssen M., et al. Steroid-free tacrolimus-based immunosuppression promotes long-term Prope/operational tolerance in pediatric liver transplantation. Pediatr Transplantation 2009; 13: 63-64.
21. Evans HM, Kelly DA, McKiernan P.J., Hubscher S. Progressive histological damage in liver allografts following pediatric livertransplantation. Hepatology 2006; 43: 1109-1117.
22. Augustine JJ, Hricik DE Steroid withdrawal: moving on to the next questions. Am J Transplant 2009; 9: 3-4.
23. Ekong UD, Bhagat H, Alonso EM Once daily calcineurin inhibitor monotherapy in pediatric livertransplantation. Am J Transplant 2010; 10: 883-888.
24. Starzl TE. Acquired immunologic tolerance: with particular reference to transplantation. Immunol Res 2007; 38 (1-3): 6-41.
25. Orlando G, Soker S, Wood K. Operational tolerance after livertransplantation. J Hepatol 2009; 50: 1247-1257.
26. Yoshitomi M, Koshiba T, Haga H, et al. Requirement of protocol biopsy before and after complete cessation of immunosuppression after liver transplantation. Transplantation 2009; 87: 606-614.
27. Lee JH, Lee SK, Lee H.J., et al. Withdrawal of immunosuppression in pediatric liver transplant recipients in Korea. Yonsei Med J 2009; 50: 784-788.
28. Feng S, Ekong U, Lobritto S., Demetris A, Rosenthal P, Alonso E., Tchao N. Immunosuppression withdrawal in pediatric recipients of parental living donor livertransplants: preliminary results of a pilot study. (Abstract #189) American Transplant Congress, Boston, Massachusetts, 30 May -3 June 2009.
29. Donckier V, Sanchez-Fueyo A, Craciun L., et al. Induction of tolerance in solid organ transplantation: the rationale to develop clinical protocols in liver transplantation. Transplant Proc 2009; 41: 603-606.
30. Barrera-Pulido L., Espinosa-Aguilar MD, Marin D., et al. Influence of mycophenolate mofetil on preservation of kidney function in liver transplant patients. Transplant Proc 2010; 42: 651-655.
31. Stevens RB. Modern approaches to combining sirolimus with calcineurin inhibitors. Transplant Proc 2008; 40: S21-S24.
32. Sindhi R, Seward J, Mazariegos G., et al. Replacing calcineurin inhibitors with mTOR inhibitors in children. Pediatr Transpl 2005; 9: 391-397.
33. Gibelli NEM, Tannuri U, Pinho-Apezzato ML, et al. Sirolimus in pediatric liver transplantation: a single-center experience. Transplant Proc 2009; 41: 901-903.
34. Toso C, Merani S, Bigam D.L., et al. Sirolimus-based immunosuppression is associated with increased survival after livertransplantation for hepatocellular carcinoma. Hepatology 2010; 51: 1237-1243.
35. Scott KL, Kabbarah O, Liang M-C, et al. GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer. Nature 2009; 459: 1085-1090.
36. Monaco AP. The role of mTOR inhibitors in the management of posttransplant malignancy. Transplantation 2009; 87: 157-163.
37. Simons LE, Anglin G, Warshaw B.L., et al. Understanding the pathway between the transplant experience and health-related quality of life outcomes in adolescents. Pediatr Transplant 2008; 12: 187-193.
38. A study of a modified-release tacrolimus based immunosuppression regimen in stable pediatric liver transplant patients. Identifier: NCT00282256 @ ClinicalTrials.gov. Last Updated 17 May 2010.
39. Zarkhin V, Chalasani G, Sarwal MM The yin and yang of B cells in graft rejection and tolerance. Transplant Rev (Orlando) 2010; 24: 67-78.
40. Pescovitz MD. Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action. Am J Transplant 2006; 6 (5 PART 1): 859-866.
41. Zarkhin V, Li L, Kambham N., et al. A randomized, prospective trial of rituximab for acute rejection in pediatric renal transplantation. Am J Transplant 2008; 8: 2607-2617.
42. Perry DK, Burns JM, Pollinger H.S., et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 2009; 9: 201-209.
43. Kim JS, Lee JI, Shin J.Y., et al. Bortezomib can suppress activation of rapamycin-resistant memory T cells without affecting regulatory T-cell viability in nonhuman primates. Transplantation 2009; 88: 1349-1359.
44. Murata K, Baldwin WM III. Mechanisms of complement activation, C4d deposition, and their contribution to the pathogenesis of antibody-mediated rejection. Transplant Rev (Orlando) 2009; 23: 139-150.
45. Sis B, Mengel M, Haas M., et al. Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 2010; 10: 464-471.
46. Locke JE, Magro CM, Singer A.L., et al. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant 2009; 9: 231-235.
47. Chan AC, Carter PJ Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 2010; 10: 301-316.
48. Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10: 535-546.
49. Aoyagi T, Yamashita K, Suzuki T., et al. A human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys: induction and maintenance therapy. Am J Transplant 2009; 9: 1732-1741.
50. Vincenti F, Mendez R, Pescovitz M., et al. A phase I/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation. Am J Transplant 2007; 7: 1770-1777.
51. Weaver TA, Charafeddine AH, Agarwal A, et al. Alefacept promotes co-stimulation blockade based allograft survival in nonhuman primates. Nat Med 2009; 15: 746-749.
52. Harris A, Krams SM, Martinez OM MicroRNAs as immune regulators: implications for transplantation. Am J Transplant 2010; 10: 713-719.
53. Wu H, Neilson JR, Kumar P, et al. miRNA profiling of naive, effector and memory CD8 T cells. PLoS ONE 2007; 2: e1020.
54. Kim SS, Ye C, Kumar P., et al. Targeted delivery of siRNA to macrophages for anti-inflammatory treatment. Mol Ther 2010; 18: 993-1001.